Discovery of EST73502, a Dual μ-Opioid Receptor Agonist and σ 1 Receptor Antagonist Clinical Candidate for the Treatment of Pain.

Autor:	García M; ESTEVE Pharmaceuticals S.A., Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain.; WELAB, Parc Científic Barcelona, C/Baldiri Reixac 4-8, 08028 Barcelona, Spain., Virgili M; Enantia, S.L., Carrer Baldiri Reixac, 10, Parc Científic de Barcelona, 08028 Barcelona, Spain., Alonso M; Enantia, S.L., Carrer Baldiri Reixac, 10, Parc Científic de Barcelona, 08028 Barcelona, Spain., Alegret C; Enantia, S.L., Carrer Baldiri Reixac, 10, Parc Científic de Barcelona, 08028 Barcelona, Spain., Farran J; Enantia, S.L., Carrer Baldiri Reixac, 10, Parc Científic de Barcelona, 08028 Barcelona, Spain., Fernández B; ESTEVE Pharmaceuticals S.A., Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain.; WELAB, Parc Científic Barcelona, C/Baldiri Reixac 4-8, 08028 Barcelona, Spain., Bordas M; ESTEVE Pharmaceuticals S.A., Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain.; WELAB, Parc Científic Barcelona, C/Baldiri Reixac 4-8, 08028 Barcelona, Spain., Pascual R; ESTEVE Pharmaceuticals S.A., Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain.; WELAB, Parc Científic Barcelona, C/Baldiri Reixac 4-8, 08028 Barcelona, Spain., Burgueño J; ESTEVE Pharmaceuticals S.A., Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain.; WELAB, Parc Científic Barcelona, C/Baldiri Reixac 4-8, 08028 Barcelona, Spain., Vidal-Torres A; ESTEVE Pharmaceuticals S.A., Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain.; WELAB, Parc Científic Barcelona, C/Baldiri Reixac 4-8, 08028 Barcelona, Spain., Fernández de Henestrosa AR; ESTEVE Pharmaceuticals S.A., Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain.; WELAB, Parc Científic Barcelona, C/Baldiri Reixac 4-8, 08028 Barcelona, Spain., Ayet E; ESTEVE Pharmaceuticals S.A., Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain.; WELAB, Parc Científic Barcelona, C/Baldiri Reixac 4-8, 08028 Barcelona, Spain., Merlos M; ESTEVE Pharmaceuticals S.A., Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain.; WELAB, Parc Científic Barcelona, C/Baldiri Reixac 4-8, 08028 Barcelona, Spain., Vela JM; ESTEVE Pharmaceuticals S.A., Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain.; WELAB, Parc Científic Barcelona, C/Baldiri Reixac 4-8, 08028 Barcelona, Spain., Plata-Salamán CR; ESTEVE Pharmaceuticals S.A., Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain., Almansa C; ESTEVE Pharmaceuticals S.A., Torre Esteve, Passeig de la Zona Franca, 109, 08038 Barcelona, Spain.; WELAB, Parc Científic Barcelona, C/Baldiri Reixac 4-8, 08028 Barcelona, Spain.
Jazyk:	angličtina
Zdroj:	Journal of medicinal chemistry [J Med Chem] 2020 Dec 24; Vol. 63 (24), pp. 15508-15526. Date of Electronic Publication: 2020 Oct 16.
DOI:	10.1021/acs.jmedchem.0c01127
Abstrakt:	The synthesis and pharmacological activity of a new series of 4-alkyl-1-oxa-4,9-diazaspiro[5.5]undecane derivatives as potent dual ligands for the σ 1 receptor (σ 1 R) and the μ-opioid receptor (MOR) are reported. A lead optimization program over the initial 4-aryl analogues provided 4-alkyl derivatives with the desired functionality and good selectivity and ADME profiles. Compound 14u (EST73502) showed MOR agonism and σ 1 R antagonism and a potent analgesic activity, comparable to the MOR agonist oxycodone in animal models of acute and chronic pain after single and repeated administration. Contrary to oxycodone, 14u produces analgesic activity with reduced opioid-induced relevant adverse events, like intestinal transit inhibition and naloxone-precipitated behavioral signs of opiate withdrawal. These results provide evidence that dual MOR agonism and σ 1 R antagonism may be a useful strategy for obtaining potent and safer analgesics and were the basis for the selection of 14u as a clinical candidate for the treatment of pain.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu